#ACC26
LightNews LightNews
dunderklumpen.bsky.social
#AChristmasCarol holiday reading with a fantastic cast! Streaming tickets can be bought here:
watch.broadwayunlocked.com/acc26/a-chri...
A Christmas Carol Live: Bryan Cranston, Jean Smart & More
Live from Hollywood Dec 17, 7pm PT: A Christmas Carol with Bryan Cranston, Jean Smart, Noah Wyle, Clancy Brown & more. Tickets on Broadway Unlocked.
watch.broadwayunlocked.com
November 3, 2026 at 7:57 PM
philsan.bsky.social
ACC26, (ABBUC Creative Competition 2026), pixel art by Buddy for #Atari8bit computers. Check out colors and overscan allowed by these 1979 machines #atari #pixelart
June 2, 2026 at 3:33 PM
ase360.bsky.social
Kian-Keong Poh, MA, MD, MS, FRCP, FASE and ASE President David Wiener. MD, FASE catch up at #ACC26!
March 30, 2026 at 4:54 PM
ase360.bsky.social
ASE President David Wiener, MD, FASE and ASE President Elect Cynthia Taub, MBA, MD, FASE joined the Imaging Council's meet-up at #ACC26!
March 30, 2026 at 4:49 PM
jamacardiology.com
Early and continuous acoramidis treatment in #ATTRCM yields sustained reductions in mortality and cardiovascular hospitalization, stabilizes biomarkers and health status, and exhibits durable safety through 54 months.

#ACC26 @accintouch.bsky.social

ja.ma/4bGqr9d
JAMA Cardiology article presents Kaplan-Meier curves for time to all-cause mortality (ACM) and cardiovascular-related mortality (CVM) through month 54. Graphs compare continuous acoramidis to placebo, showing survival probability over time with stratified Cox regression analysis.
March 30, 2026 at 7:00 PM
jamacardiology.com
📚🫀 Read all the JAMA Cardiology papers presented today at #ACC26, including Pregnancy-Associated Spontaneous Coronary Artery Dissection.

ja.ma/4dgCVpg
Red background with 'Read papers from the JAMA Network' in white. 'ACC' in a black box and 'JN' in a white circle are in the top corners.
March 29, 2026 at 9:00 PM
jamacardiology.com
At #ACC26?

📚 Caffeinated Coffee Consumption or Abstinence to Reduce Atrial Fibrillation (DECAF RCT)
From JAMA
🔓 Free to read online

ja.ma/4sIaUM6
Red background with text "Read papers from the JAMA Network" in white. "ACC" logo on the top left in a black square and "JN" logo on the top right in a white circle.
March 29, 2026 at 5:00 PM
jamacardiology.com
💬 Editorial: In the VESALIUS-CV trial, evolocumab reduced major cardiovascular events in high-risk patients, including those with long-standing #diabetes, already receiving statins but not reaching LDL-C targets.

#ACC26 @accintouch.bsky.social

ja.ma/4s2r6Xs
A JAMA editorial published online March 28, 2026, titled 'Lipid Lowering in 2026: Still Asking When, in Whom, and How' by Philip Greenland, MD; Donald M. Lloyd-Jones, MD, MSc, discussing preventive cardiology and treatment guidelines.
March 28, 2026 at 9:10 PM
jamacardiology.com
From @jama.com: 📊 Research Summary: Among adults with high-risk #diabetes and elevated LDL cholesterol but no significant atherosclerosis, adding evolocumab to statin therapy reduced first major cardiovascular events.

#ACC26 @accintouch.bsky.social

ja.ma/4lVsppF
JAMA Research Summary: Evolocumab reduces cardiovascular events in patients with diabetes. Study: Evolocumab (1849 patients) vs Placebo (1806 patients). 5-year estimates: 3-P MACE Evolocumab 5.0% vs Placebo 7.1%, 4-P MACE Evolocumab 7.6% vs Placebo 10.5%.
March 28, 2026 at 9:05 PM
jamacardiology.com
From @jama.com: Among adults with high-risk #diabetes and elevated LDL cholesterol, evolocumab combined with statins reduced rates of major cardiovascular events compared to statin alone.

#ACC26 @accintouch.bsky.social

ja.ma/4lZZT6f
Infographic showing JAMA study results on evolocumab's effect on cardiovascular events. Population: 2066 females, 1589 males. Intervention: 1849 evolocumab, 1806 placebo. Findings: Evolocumab reduced 3-P MACE to 5.0% vs. 7.1% placebo, and 4-P MACE to 7.6% vs. 10.5%.
March 28, 2026 at 9:00 PM
jamacardiology.com
📍 At #ACC26? Attend the JAMA_current Late-Breaking Clinical Trials session:

📅 Mar 28 | 3:35 to 4:45 PM
📍 Main Tent, Great Hall

Chaired by JAMA Executive Editor Greg Curfman, MD
JAMA Network presents Late-Breaking Clinical Trials II (Session 105), Saturday, March 28, 3:45 – 4:45 p.m. CT, Main Tent, Great Hall. Features Gregory Curfman, MD, JAMA Executive Editor.
March 28, 2026 at 7:45 PM
jamacardiology.com
💬 Editor's Note: In HFmrEF/HFpEF, modest clinical and biomarker declines precede sudden death, but similar patterns occur before other fatal outcomes, limiting risk prediction specificity.

#ACC26 @accintouch.bsky.social

ja.ma/41jAOK9
JAMA Cardiology presents an Editor's Note: "Rethinking Sudden Death in Heart Failure With Mildly Reduced or Preserved Ejection Fraction" by Gregg C. Fonarow, MD@1,2. Published online March 28, 2026, doi: 10.1001/jamacardio.2026.0692.
March 28, 2026 at 7:30 PM
jamacardiology.com
Biomarker-driven #HFpEF risk stratification using the EMPEROR-Preserved model identified higher absolute benefit from finerenone for patients at greatest baseline risk, while relative treatment effect remained uniform.

#ACC26 @accintouch.bsky.social

ja.ma/4tjaGuN
JAMA Cardiology article, published March 28, 2026, titled "EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial." Figure 1 shows line graphs of incidence rates of clinical outcomes for heart failure patients, based on EMPEROR-Preserved risk scores.
March 28, 2026 at 7:20 PM
jamacardiology.com
In #HFmrEF/#HFpEF, sudden death was usually preceded by modest worsening of symptoms, declining quality of life, and rising NT-proBNP, similar to other causes of death, limiting prediction specificity.

#ACC26 @accintouch.bsky.social

ja.ma/41tWm6G
JAMA Cardiology: Biomarker, Functional Status, and Quality-of-Life Trajectories Before Modes of Death in Heart Failure. Figure 1 and 2 show cubic splines depicting trajectories in the period preceding sudden death. NYHA class and KCCQ-TSS graphs are displayed.
March 28, 2026 at 7:15 PM
jamacardiology.com
💬 Editor's Note: Dual incretin therapy may improve cardiorenal outcomes when broader endpoints are considered, but robust superiority trials are needed for #Type2Diabetes.

#ACC26 @accintouch.bsky.social

ja.ma/3O6evo0
JAMA Cardiology Editor's Note: "Exploring Additional Cardiorenal Outcomes—Beyond the Primary Composite End Point" by Gregg C. Fonarow, MD@1, John J. V. McMurray, MD@2. Published Online: March 28, 2026.
March 28, 2026 at 6:50 PM
jamacardiology.com
In patients w/ type 2 #diabetes and #cardiovascular disease, the dual #GLP1/glucose-dependent insulinotropic polypeptide agonist #tirzepatide was associated w/ a lower incidence of major cardiorenal events compared with dulaglutide.

#ACC26 @accintouch.bsky.social

ja.ma/4s1pCfZ
JAMA Cardiology RCT shows cardiorenal outcomes with tirzepatide vs. dulaglutide in diabetes/cardiovascular disease patients. Population: 9348 male, 3817 female. Intervention: 13299 randomized. Graph compares cumulative incidence of both.
March 28, 2026 at 6:45 PM
jamacardiology.com
📍 At #ACC26?

Join the Joint @accintouch.bsky.social / JAMA Late‑Breaking Clinical Trials II session:

📅 Today, March 28
⏰ 3:45–4:45 PM CT
📍 Main Tent, Great Hall

Chaired by JAMA Executive Editor Greg Curfman, MD.
Advertisement for JAMA Network's "Late-Breaking Clinical Trials II (Session 105)" on Saturday, March 28, from 3:45 – 4:45 p.m. CT, Main Tent, Great Hall. Features Gregory Curfman, MD, JAMA Executive Editor.
March 28, 2026 at 4:45 PM
jamacardiology.com
📍 #ACC26 attendees, don’t miss the JAMA Late‑Breaking Clinical Trials II session:

📅 Mar 28 | 3:45–4:45 PM CT

📍 Main Tent, Great Hall

Chaired by JAMA Executive Editor Greg Curfman, MD.
JAMA Network presents Late-Breaking Clinical Trials II (Session 105) on Saturday, March 28, from 3:45 – 4:45 p.m. CT at the Main Tent, Great Hall. Features Gregory Curfman, MD, JAMA Executive Editor.
March 28, 2026 at 1:45 PM
jamacardiology.com
📍 At #ACC26? Join the JAMA Late‑Breaking Clinical Trials II session:

📅 Sat, Mar 28 | 3:45–4:45 PM CT
📍 Main Tent, Great Hall

Chaired by JAMA Executive Editor Greg Curfman, MD
Advertisement for JAMA Network's Late-Breaking Clinical Trials II (Session 105) on Saturday, March 28, from 3:45 – 4:45 p.m. CT, at Main Tent, Great Hall. Image of Gregory Curfman, MD, JAMA Executive Editor.
March 28, 2026 at 11:45 AM
jamacardiology.com
Attending #ACC26? Visit our attendee page to:

📚 Read recent articles & podcasts
🤝 Meet editors
✍️ Find author resources

ja.ma/4bBsSK8
The image features text on a red background promoting reading papers from the JAMA Network. Logos for ACC and JN are in the upper corners. Text reads: Read papers from the JAMA Network™
March 27, 2026 at 5:00 PM
jamacardiology.com
Heading to #ACC26?

🤝 Meet Robert Harrington, MD, Associate Editor, JAMA Cardiology
📍 Booth 1906
⏰ Sun, Mar 29 | 10:00 -10:30 AM
Advertisement for JAMA Cardiology's "Meet the Editor" event, Sunday, March 29, 10:00-10:30 AM with Robert Harrington, MD, JAMA Cardiology Associate Editor. "VISIT US IN BOOTH #1906"
March 27, 2026 at 4:00 PM
thelancet.com
Clopidogrel vs aspirin after PCI:

10-year HOST-EXAM follow-up shows lower ischemic and bleeding events with clopidogrel—but no difference in mortality.

Read more: spkl.io/63327ANGO9 #ACC26
Infographic explainer for aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial
April 12, 2026 at 1:33 PM
thelancet.com
PCI before TAVI—necessary?

In patients with CAD, deferring PCI was noninferior to a PCI-first strategy at 1 year for the composite of death, MI, stroke, and major bleeding.

spkl.io/63327A0CAF #ACC26
Infographic explainer for deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial
March 29, 2026 at 9:05 PM
thelancet.com
Clopidogrel vs aspirin after PCI:

10-year HOST-EXAM follow-up shows lower ischemic and bleeding events with clopidogrel—but no difference in mortality.

Read more: spkl.io/63327A0hCP #ACC26
Infographic explainer for aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial
March 29, 2026 at 5:17 PM
maurosotomd.bsky.social
👋🏽 Hola a todos! 🫀He sido seleccionado como Embajador de Redes Sociales para el Congreso Americano de Cardiología #ACC26 que se realizará en New Orleans, Louisiana!

📅 Entre el 28 y el 30 de Marzo estaré compartiendo con ustedes las actualizaciones, atentos a las redes!
@accintouch.bsky.social
December 15, 2025 at 5:24 PM